Research programme: RNA-targeted therapeutics - Andes Biotechnologies

Drug Profile

Research programme: RNA-targeted therapeutics - Andes Biotechnologies

Alternative Names: Andes 1560

Latest Information Update: 17 Jun 2015

Price : $50

At a glance

  • Originator Andes Biotechnologies
  • Class Antisense oligoribonucleotides; Antisense RNA
  • Mechanism of Action Apoptosis stimulants; RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Jun 2015 Research programme: RNA-targeted therapeutics - Andes Biotechnologies is available for licensing as of 16 Jun 2015. http://andesbiotechnologies.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top